GH Research PLCGHRS
What GH Research PLC does.
We are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. Our initial focus is on developing our
Our portfolio currently includes GH001, our proprietary inhalable mebufotenin product candidate and GH002, our proprietary intravenous mebufotenin product candidate. While GH001 is currently
delivered via a vaporization device produced by a third party, we are developing a proprietary aerosol delivery device, which is currently in clinical investigation in Europe. We have completed two Phase 1 healthy volunteer clinical trials for
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$446,000 | -$9.2M | -$22.5M | -$35.6M | -$39.0M | -$48.3M |
| Free cash flow | -$330,000 | -$15.4M | -$26.3M | -$33.4M | -$42.3M | -$43.7M |
More on GHRS.
- GH Research PLC summary
- GH Research PLC financial statements
- GH Research PLC key metrics
- GH Research PLC health scores and style box
- GH Research PLC earnings
- GH Research PLC dividends
- GH Research PLC valuation
- GH Research PLC ownership and insiders
- GH Research PLC peers
Figures from GH Research PLC's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.